{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'Criteria for evaluation:', 'Efficacy:', 'Number of HAE attacks and related details (timing, duration of symptoms, anatomical location,', 'treatment used and emergency room visits and hospitalizations (through Week 96), number of days', 'with HAE symptoms, number of subjects who are attack-free, assessment of attack severity, and', 'discontinuations due to lack of efficacy (through Week 48).', 'Safety:', 'AEs, laboratory analyses (clinical chemistry, hematology, coagulation, urinalysis, creatine', 'kinase-MB, troponin I and T, neutrophil gelatinase-associated lipocalin), vital signs, ECGs, and', 'physical examinations. An independent Data Monitoring Committee (DMC) will periodically review', 'safety data in accordance with a DMC Charter. Relationships between safety assessment findings and', 'human leukocyte antigen typing results may be examined on a meta-study basis.', 'Health Outcomes:', 'AE-QoL, EQ-5D-5L, TSQM, WPAI questionnaire scores.', 'Pharmacodynamics:', 'Kallikrein inhibition.', 'Additional exploratory assays to elucidate PD properties of BCX7353 may also be conducted on', 'plasma samples drawn for PD analyses.', 'Pharmacokinetics (PK):', 'A blood sample for BCX7353 concentration will be drawn. Population PK of BCX7353 will be', 'evaluated on a meta-study basis.', 'Statistical methods:', 'The primary study hypothesis is that the rate of HAE attacks during 24 weeks of prophylactic', 'BCX7353 (at either 150 or 110 mg QD) will be superior to placebo. The primary efficacy endpoint is', 'the monthly investigator-confirmed HAE attack rate in the entire treatment period (Day 1 [post-dose]', 'to Day 168) in the intent-to-treat population, which includes all randomized subjects.', 'Each BCX7353 dose will be compared to placebo in the primary analysis. The primary analysis of', 'treatment-effect will be performed using a Poisson regression model. The stratification variable', '(baseline monthly attack rate) will be included as a covariate and the logarithm of duration on', 'treatment will be included as an offset variable. The estimated treatment differences in attack rate', 'ratio (BCX7353 over placebo rate ratio) and their associated 95% confidence intervals will be', 'provided. Monthly will be defined as 4 weeks.', 'Assuming a normalized placebo attack rate of 1 unit and a common standard deviation of 0.55 units', 'for BCX7353 and placebo attack rates, a sample size of 32 subjects will have 94% power to detect a', '> 50% attack rate reduction (a treatment difference of 0.5 units) between BCX7353 and placebo,', 'based on a 2-sided test at significance level of 0.05. To account for multiplicity, the Hochberg step-up', 'procedure will be used to adjust for the 2 active doses vs. placebo comparisons.', 'Safety assessments, data from HAE attack diaries and QoL questionnaires will be summarized and', 'listed. PD data will be summarized in tables and figures.', 'The totality of data will be analyzed at the end of the study.', '15']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '3.', 'TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF', 'FIGURES', '1.1.', 'Protocol Approval Signature Page', '3', '1.2.', 'Clinical Study Protocol Agreement', '4', '2.', 'SYNOPSIS', '5', '3.', 'TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES', '16', 'LIST OF TABLES', '21', 'LIST OF FIGURES', '21', '4.', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', '22', '5.', 'INTRODUCTION', '25', '5.1.', 'Background', '25', '5.2.', 'Nonclinical Findings for BCX7353', '25', '5.3.', 'Clinical Findings for BCX7353', '26', '5.3.1.', 'Summary of Ongoing Study BCX7353-302', '27', '5.3.2.', 'Summary of Study BCX7353-203', '28', '5.3.3.', 'Data Monitoring Committee Review of Ongoing Studies BCX7353-302 and', 'BCX7353-204', '29', '5.4.', 'Rationale for Study', '29', '5.4.1.', 'Rationale for Study Design', '30', '5.4.2.', 'Rationale for BCX7353 Doses and Regimen', '30', '5.4.3.', 'Study Population Rationale', '31', '5.4.4.', 'Rationale for Control Group and Prohibition of Current Prophylactic', 'Medications', '32', '5.4.5.', 'BCX7353 Benefit-Risk Analysis', '33', '5.4.6.', 'Benefits of Trial Participation', '33', '5.4.7.', 'Overall Benefit-Risk Assessment', '33', '6.', 'TRIAL OBJECTIVES', '33', '6.1.', 'Objectives', '33', '6.1.1.', 'Part 1 Primary Objective', '33', '6.1.2.', 'Part 1 Secondary Objectives', '33', '6.1.3.', 'Part 2 Primary Objective', '33', '6.1.4.', 'Part 2 Secondary Objectives', '34', '6.1.5.', 'Part 3 Primary Objective', '34', '16']\n\n###\n\n", "completion": "END"}